Earning Analysis
Welcome to our in-depth analysis of Apellis Pharmaceuticals Inc(APLS) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Apellis Pharmaceuticals Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q3 | 2025-10-30 | Pre-Market | 1.03 | 1.67 | +62.14 | 409.16M | 458.58M | +12.08 | -31.01 | -31.88 |
| FY2025Q2 | 2025-07-31 | Pre-Market | -0.44 | -0.33 | +25.00 | 188.65M | 178.49M | -5.38 | +17.58 | +27.37 |
| FY2025Q1 | 2025-05-07 | Pre-Market | -0.36 | -0.74 | -105.56 | 194.88M | 166.80M | -14.41 | -5.91 | -8.37 |
| FY2024Q4 | 2025-02-28 | Pre-Market | -0.39 | -0.29 | +25.64 | 197.91M | 212.53M | +7.38 | -3.27 | -2.62 |
| FY2024Q3 | 2024-11-05 | Pre-Market | -0.32 | -0.46 | -43.75 | 199.82M | 196.83M | -1.50 | -1.70 | +3.57 |
| FY2024Q2 | 2024-08-01 | - | -0.33 | -0.28 | +15.15 | 191.31M | 199.69M | +4.38 | -9.09 | -15.18 |
| FY2024Q1 | 2024-05-07 | - | -0.54 | -0.54 | - | 164.26M | 172.33M | +4.91 | -10.06 | -11.88 |
| FY2023Q4 | 2024-02-27 | - | -0.66 | -0.73 | -10.61 | 143.59M | 146.38M | +1.94 | -3.32 | -9.90 |
| FY2023Q3 | 2023-11-01 | - | -0.84 | -1.17 | -39.29 | 99.05M | 110.40M | +11.45 | +2.55 | -2.79 |
| FY2023Q2 | 2023-07-31 | - | -1.35 | -1.02 | +24.44 | 71.12M | 94.97M | +33.53 | -19.58 | -23.39 |
APLS Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Apellis Pharmaceuticals Inc reported performance for FY2025Q3, announced on 2025-10-30. The company achieved an EPS of 1.67, compared to analyst estimates of 1.03 by 62.14% . Revenue for the quarter reached 458.58M compared to expectations of 409.16M by 12.08% .
The stock price reacted with a -31.01% one-day change and a -31.88% five-day change following the earnings release. These movements reflect market reaction in Apellis Pharmaceuticals Inc growth trajectory and strategic initiatives.
APLS Earnings Forecast
Looking ahead, Apellis Pharmaceuticals Inc(APLS) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 201.11M and an EPS of -0.38.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 5.92%, while EPS estimates have been Revise Downward by -178.08%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Downward by -5.35% . These revisions correlate with a -21.12% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Apellis Pharmaceuticals Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between APLS's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+5.92%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-178.08%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Downward
-5.35%
In Past 3 Month
Stock Price
Go Down
-21.12%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:990.82M
--
EPS Estimate-Annual FY 2025:0.26
—
Stock Price22.19
APLS Revenue and EPS Performance: A Historical Perspective
Apellis Pharmaceuticals Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-10-30,Pre-Market):
EPS: 1.67 (Actual) vs.1.03 (Estimate) (62.14%)
Revenue: 458.58M (Actual) vs. 409.16M (Estimate) (12.08%)
Price Reaction: -31.01%(1-Day), -31.88%(5-Day)
FY2025Q2 (2025-07-31,Pre-Market):
EPS: -0.33 (Actual) vs.-0.44 (Estimate) (25.00%)
Revenue: 178.49M (Actual) vs. 188.65M (Estimate) (-5.38%)
Price Reaction: 17.58%(1-Day), 27.37%(5-Day)
FY2025Q1 (2025-05-07,Pre-Market):
EPS: -0.74 (Actual) vs.-0.36 (Estimate) (-105.56%)
Revenue: 166.80M (Actual) vs. 194.88M (Estimate) (-14.41%)
Price Reaction: -5.91%(1-Day), -8.37%(5-Day)
Earnings Reaction
The chart below shows how APLS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, APLS sees a +12.10% change in stock price 10 days leading up to the earnings, and a +3.17% change 10 days following the report. On the earnings day itself, the stock moves by -6.38%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 3.57% on the day following the earnings release and then changed by -4.44% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Apellis Pharmaceuticals Inc (APLS) Q3 2025 Earnings Call Summary
Neutral
2025-10-30
The earnings call reflects a mixed sentiment. While there are positive developments like the expected transition of patients to commercial growth and new trials, concerns exist regarding revenue segmentation and the timeline for new product launches. The Q&A session reveals uncertainties about market growth and product availability, which tempers enthusiasm. Given the lack of strong catalysts or significant new partnerships, the overall sentiment is neutral, with no clear indication of a strong positive or negative stock price movement.
Apellis Pharmaceuticals Inc (APLS) Q2 2025 Earnings Call Summary
Neutral
2025-08-02
The earnings call summary highlights stable financial performance and market leadership in SYFOVRE. However, the Q&A section reveals concerns about funding gaps and vague management responses on cost management and patient assistance. Although the company maintains leadership in its market, uncertainties regarding patient funding and unclear guidance on expenses temper positive sentiments. With no new partnerships or significant announcements to drive stock price, the overall sentiment remains neutral.
Apellis Pharmaceuticals Inc (APLS) Q1 2025 Earnings Call Summary
Negative
2025-05-07
The earnings call reveals several concerns: revenue shortfalls due to funding shortages, inventory issues, and competitive pressures. The Q&A section highlights unresolved co-pay assistance problems and lack of guidance on SYFOVRE sales. Despite some positive aspects like strong injection demand and cash position, the negative factors, including regulatory risks and economic challenges, outweigh the positives. Without a clear resolution to these issues, the stock is likely to experience a negative reaction over the next two weeks.
Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Summary
Neutral
2025-03-01
The earnings call presents a mixed picture: strong revenue growth and a solid cash position are offset by regulatory issues, competitive pressures, and financial risks. The Q&A reveals management's optimism but lacks clarity on market share specifics and financial guidance. The absence of a shareholder return plan and potential temporary Q1 challenges further contribute to a neutral sentiment. With no market cap data, the stock's reaction is uncertain, but the overall outlook is balanced.
Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Summary
Positive
2025-03-01
The earnings call highlights strong financial performance, with significant growth in US net revenue and a positive EPS surprise. SYFOVRE's market share and sales remain robust, and there is optimism for EMPAVELI's future launch. Despite some supply chain challenges and regulatory uncertainties, the overall sentiment is positive due to strong market positioning and growth potential in rare diseases. The absence of a share repurchase program is a minor negative, but the strong financial metrics and optimistic guidance support a positive outlook.
Apellis Pharmaceuticals, Inc. (APLS) Q3 2024 Earnings Call Summary
Neutral
2024-11-05
The earnings call reflects mixed signals. Strong revenue growth and market leadership for SYFOVRE are positive, but the lack of guidance and vague responses on key metrics like gross to net adjustments create uncertainty. The absence of a shareholder return plan and the impact of economic factors on revenue are additional concerns. While there is potential for market expansion, the competitive landscape and contracting decisions temper enthusiasm. Overall, the sentiment is neutral, with no strong catalysts to drive significant short-term stock price movement.
Apellis Pharmaceuticals, Inc. (APLS) Q2 2024 Earnings Call Summary
Neutral
2024-08-01
The earnings call reveals strong financial performance with increased revenues and liquidity improvements, but also highlights uncertainties such as regulatory issues in Europe and competitive market pressures. The lack of a share repurchase program and unclear guidance on future cash flow and EU approval adds to the uncertainty. The Q&A session did not provide clarity on these concerns, maintaining a neutral outlook due to mixed signals and potential risks.
People Also Watch
FAQ
What were the key highlights of APLS’s latest earnings report for FY2025Q3?
How did APLS’s stock price react after the FY2025Q3 earnings release?
What are the revenue and EPS estimates for APLS for 2025/Q4?
How does APLS’s stock price correlate with earnings forecast revisions?
What should investors expect from APLS’s next earnings report?